Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

Br J Dermatol. 2015 Apr;172(4):867-77. doi: 10.1111/bjd.13717.


Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients, bullae may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. Our consensus for the treatment of bullous pemphigoid has been developed under the guidance of the European Dermatology Forum in collaboration with the European Academy of Dermatology and Venereology. It summarizes evidence-based and expert-based recommendations.

Publication types

  • Practice Guideline

MeSH terms

  • Administration, Cutaneous
  • Adrenal Cortex Hormones / administration & dosage
  • Clinical Laboratory Techniques / methods
  • Consensus
  • Dermatologic Agents / therapeutic use
  • Dietary Supplements
  • Humans
  • Hydrotherapy / methods
  • Medical History Taking / methods
  • Patient Care Team
  • Patient Education as Topic / methods
  • Pemphigoid, Bullous / diagnosis
  • Pemphigoid, Bullous / therapy*
  • Physical Examination / methods
  • Self-Help Groups
  • Steroids / administration & dosage


  • Adrenal Cortex Hormones
  • Dermatologic Agents
  • Steroids